122 related articles for article (PubMed ID: 38402864)
1. Understanding Social, Cultural, and Religious Factors Influencing Medical Decision-Making on BRCA1/2 Genetic Testing in the Orthodox Jewish Community.
Yi H; Trivedi MS; Crew KD; Schechter I; Appelbaum P; Chung WK; Allegrante JP; Kukafka R
Public Health Genomics; 2024; 27(1):57-67. PubMed ID: 38402864
[TBL] [Abstract][Full Text] [Related]
2. Population-Based Study of Attitudes toward BRCA Genetic Testing among Orthodox Jewish Women.
Tang EY; Trivedi MS; Kukafka R; Chung WK; David R; Respler L; Leifer S; Schechter I; Crew KD
Breast J; 2017 May; 23(3):333-337. PubMed ID: 27900810
[TBL] [Abstract][Full Text] [Related]
3. Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2.
Phillips KA; Warner E; Meschino WS; Hunter J; Abdolell M; Glendon G; Andrulis IL; Goodwin PJ
Clin Genet; 2000 May; 57(5):376-83. PubMed ID: 10852372
[TBL] [Abstract][Full Text] [Related]
4. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
5. Understanding Factors Associated with Uptake of BRCA1/2 Genetic Testing among Orthodox Jewish Women in the USA Using a Mixed-Methods Approach.
Trivedi MS; Colbeth H; Yi H; Vanegas A; Starck R; Chung WK; Appelbaum PS; Kukafka R; Schechter I; Crew KD
Public Health Genomics; 2018; 21(5-6):186-196. PubMed ID: 31163445
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
7. The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers.
Gal I; Gershoni Baruch R; Haber D; Dagan E; Eisenberg-Barzilai S; Zidan J; Friedman E
Fam Cancer; 2004; 3(1):11-4. PubMed ID: 15131400
[TBL] [Abstract][Full Text] [Related]
8. A population-based study of Ashkenazi Jewish women's attitudes toward genetic discrimination and BRCA1/2 testing.
Lehmann LS; Weeks JC; Klar N; Garber JE
Genet Med; 2002; 4(5):346-52. PubMed ID: 12394347
[TBL] [Abstract][Full Text] [Related]
9. Community attitudes towards a Jewish community BRCA1/2 testing program.
Cousens N; Kaur R; Meiser B; Andrews L
Fam Cancer; 2017 Jan; 16(1):17-28. PubMed ID: 27480161
[TBL] [Abstract][Full Text] [Related]
10. Orthodox Jewish Thought Leaders' Insights Regarding BRCA Mutations: A Descriptive Study.
Bressler T; Popp B
J Oncol Pract; 2017 Apr; 13(4):e303-e309. PubMed ID: 27875073
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H
Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347
[TBL] [Abstract][Full Text] [Related]
13. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.
Manchanda R; Loggenberg K; Sanderson S; Burnell M; Wardle J; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; McGuire A; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):379. PubMed ID: 25435541
[TBL] [Abstract][Full Text] [Related]
14. Impact of educational print materials on knowledge, attitudes, and interest in BRCA1/BRCA2: testing among Ashkenazi Jewish women.
Schwartz MD; Benkendorf J; Lerman C; Isaacs C; Ryan-Robertson A; Johnson L
Cancer; 2001 Aug; 92(4):932-40. PubMed ID: 11550168
[TBL] [Abstract][Full Text] [Related]
15. Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.
Bluman LG; Rimer BK; Regan Sterba K; Lancaster J; Clark S; Borstelmann N; Iglehart JD; Winer EP
Psychooncology; 2003; 12(5):410-27. PubMed ID: 12833555
[TBL] [Abstract][Full Text] [Related]
16. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
[TBL] [Abstract][Full Text] [Related]
17. Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.
Chodick G; Struewing JP; Ron E; Rutter JL; Iscovich J
Eur J Med Genet; 2008; 51(2):141-7. PubMed ID: 18158280
[TBL] [Abstract][Full Text] [Related]
18. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.
Hartge P; Struewing JP; Wacholder S; Brody LC; Tucker MA
Am J Hum Genet; 1999 Apr; 64(4):963-70. PubMed ID: 10090881
[TBL] [Abstract][Full Text] [Related]
19. Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities.
Augustyn AM; Agostino NM; Namey TL; Nair S; Martino MA
Breast Cancer Res Treat; 2011 Sep; 129(2):629-34. PubMed ID: 21607582
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue.
Rubinstein WS; Jiang H; Dellefave L; Rademaker AW
Genet Med; 2009 Sep; 11(9):629-39. PubMed ID: 19606050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
